LEARN ABOUT OUR PURPOSE & COMITTMENT TO IMPROVING PATIENT QUALITY OF LIFE
Skye Biologics, a U.S.-based leader in biotechnology, was founded in 2006 to develop and manufacture Extracellular Matrix Biologic (BioECM) products designed to engage and assist the body in its natural ability to restore damaged connective tissues.
Skye Biologics products have been used in over 200,000 tissue-repair treatments nationwide, to augment and support degenerated or damaged tissues in surgical repairs and non-operative therapy as a potential alternative to surgery.
Our product performance utilizes a complex BioActive® scaffold. The source of our biologics is derived from the human placenta, which is known to have unique immune privileged tissue remodeling potential.
Our extensive product line provides biologic solutions with ideal handling and delivery options for most clinical challenges, and applications for this technology are continually increasing. When the product is applied, it provides a native scaffold structure along with abundant growth factors and BioActive® molecules that support and restore the body's remodeling ability.
These products are utilized in the treatment of musculoskeletal injuries, nerve grafting, scar and adhesion prevention, incision and wound repair, and other applications in orthopaedic, podiatry, neuro and spine, GYN, urologic, colorectal, general, head, and neck, ocular and wound care procedures.
Skye Biologics continues to work together with physicians, hospitals, and corporate partners to identify medical needs and continue to develop and tailor our advanced BioECM® treatment technology.